Evidence map›Paper›PMID 34625487›Full record

ArticleJournal of psychiatry & neuroscience : JPN2021

The utility of maraviroc, an antiretroviral agent used to treat HIV, as treatment for opioid abuse? Data from MRI and behavioural testing in rats.

Sade C Iriah, Catarina Borges, Uri Shalev, Xuezhu Cai, Dan Madularu, Praveen P Kulkarni, Craig F Ferris

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psychiatry & neuroscience : JPN, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Sade C IriahFrom the Centre for Translational Neuroimaging, Northeastern University, Boson, Mass., USA (Iriah, Cai, Madularu, Kulkarni, Ferris); and Concordia University, Montreal, Que., Canada (Borges, Shalev). s.iriah@northeastern.edu.
Catarina BorgesFrom the Centre for Translational Neuroimaging, Northeastern University, Boson, Mass., USA (Iriah, Cai, Madularu, Kulkarni, Ferris); and Concordia University, Montreal, Que., Canada (Borges, Shalev).
Uri ShalevFrom the Centre for Translational Neuroimaging, Northeastern University, Boson, Mass., USA (Iriah, Cai, Madularu, Kulkarni, Ferris); and Concordia University, Montreal, Que., Canada (Borges, Shalev).
Xuezhu CaiFrom the Centre for Translational Neuroimaging, Northeastern University, Boson, Mass., USA (Iriah, Cai, Madularu, Kulkarni, Ferris); and Concordia University, Montreal, Que., Canada (Borges, Shalev).
Dan MadularuFrom the Centre for Translational Neuroimaging, Northeastern University, Boson, Mass., USA (Iriah, Cai, Madularu, Kulkarni, Ferris); and Concordia University, Montreal, Que., Canada (Borges, Shalev).
Praveen P KulkarniFrom the Centre for Translational Neuroimaging, Northeastern University, Boson, Mass., USA (Iriah, Cai, Madularu, Kulkarni, Ferris); and Concordia University, Montreal, Que., Canada (Borges, Shalev).
Craig F FerrisFrom the Centre for Translational Neuroimaging, Northeastern University, Boson, Mass., USA (Iriah, Cai, Madularu, Kulkarni, Ferris); and Concordia University, Montreal, Que., Canada (Borges, Shalev).
Northeastern University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMaraviroc is an antiretroviral agent and C-C chemokine coreceptor 5 (CCR5) antagonist that is currently used to treat human immunodeficiency virus. CCR5/μ-opioid receptor heterodimerization suggests that maraviroc could be a treatment for oxycodone abuse. We treated rats with maraviroc to explore its effect on oxycodone-seeking and its interference with the analgesic effects of oxycodone. We used resting-state blood-oxygen-level-dependent functional connectivity to assess the effect of maraviroc on oxycodone-enhanced coupling in the reward circuitry and performed behavioural tests to evaluate the effect of maraviroc on oxycodone rewarding properties and on oxycodone-seeking after prolonged abstinence.

methodsTwo groups of rats were exposed to 8 consecutive days of oxycodone-conditioned place preference training and treatment with maraviroc or vehicle. Two additional groups were trained to self-administer oxycodone for 10 days and then tested for drug seeking after 14 days of abstinence with or without daily maraviroc treatment. We tested the effects of maraviroc on oxycodone analgesia using a tail-flick assay. We analyzed resting-state functional connectivity data using a rat 3-dimensional MRI atlas of 171 brain areas.

resultsMaraviroc significantly decreased conditioned place preference and attenuated oxycodone-seeking behaviour after prolonged abstinence. The analgesic effect of oxycodone was maintained after maraviroc treatment. Oxycodone increased functional coupling with the accumbens, ventral pallidum and olfactory tubercles, but this was reduced with maraviroc treatment. LIMITATIONS: All experiments were performed in male rats only.

conclusionMaraviroc treatment attenuated oxycodone-seeking in abstinent rats and reduced functional coupling in the reward circuitry. The analgesic effects of oxycodone were not affected by maraviroc.

Indexed as

Analgesics, OpioidAnimalsAnti-HIV AgentsBehavior, AnimalMagnetic Resonance ImagingMaleMaravirocOpioid-Related DisordersOxycodoneRatsAnalgesics, OpioidAnti-HIV AgentsMaravirocOxycodone

Identifiers

PMID34625487
PMCPMC8526136
OpenAlexW3203462378

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.